Mary Chapman,  features writer—

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

FightMND Grant to Fund Phase 2 Study of Investigational Therapy for ALS

Continuing its support for a potential therapy for amyotrophic lateral sclerosis (ALS), Australia-based organization FightMND has granted about $700,000 to biopharmaceutical company Collaborative Medicinal Development. The money will fund a randomized, double-blind, placebo-controlled study of CuATSM, one of CMD’s lead investigational therapies. According to a news release, the…

FightMND Awards Grant to Lauren Sciences to Develop Promising ALS Therapy

The Australian non-profit organization FightMND has awarded Lauren Sciences a AU$1 million ($710,000 US) grant to further the biotechnology company’s development of a new treatment for amyotrophic lateral sclerosis (ALS). Specifically, the New York-based biotechnology company will use the funds to advance LAUR-301, a medicine that aims…